221 related articles for article (PubMed ID: 29807067)
1. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light.
Tchekalarova J; Stoynova T; Ilieva K; Mitreva R; Atanasova M
Pharmacol Biochem Behav; 2018 Aug; 171():1-9. PubMed ID: 29807067
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Vimala PV; Bhutada PS; Patel FR
Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
[TBL] [Abstract][Full Text] [Related]
3. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
Descamps A; Rousset C; Millan MJ; Spedding M; Delagrange P; Cespuglio R
Psychopharmacology (Berl); 2009 Jul; 205(1):93-106. PubMed ID: 19370342
[TBL] [Abstract][Full Text] [Related]
4. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Rainer Q; Xia L; Guilloux JP; Gabriel C; Mocaër E; Hen R; Enhamre E; Gardier AM; David DJ
Int J Neuropsychopharmacol; 2012 Apr; 15(3):321-35. PubMed ID: 21473810
[TBL] [Abstract][Full Text] [Related]
5. Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats.
Mairesse J; Silletti V; Laloux C; Zuena AR; Giovine A; Consolazione M; van Camp G; Malagodi M; Gaetani S; Cianci S; Catalani A; Mennuni G; Mazzetta A; van Reeth O; Gabriel C; Mocaër E; Nicoletti F; Morley-Fletcher S; Maccari S
Int J Neuropsychopharmacol; 2013 Mar; 16(2):323-38. PubMed ID: 22310059
[TBL] [Abstract][Full Text] [Related]
6. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
7. Agomelatine effects on fat-enriched diet induced neuroinflammation and depression-like behavior in rats.
Rebai R; Jasmin L; Boudah A
Biomed Pharmacother; 2021 Mar; 135():111246. PubMed ID: 33453676
[TBL] [Abstract][Full Text] [Related]
8. [Agomelatine: the first "melatoninergic" antidepressant].
Bánki MC
Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
[TBL] [Abstract][Full Text] [Related]
9. Like melatonin, agomelatine (S20098) increases the amplitude of oscillations of two clock outputs: melatonin and temperature rhythms.
Castanho A; Bothorel B; Seguin L; Mocaër E; Pévet P
Chronobiol Int; 2014 Apr; 31(3):371-81. PubMed ID: 24328729
[TBL] [Abstract][Full Text] [Related]
10. The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
De Berardis D; Marini S; Fornaro M; Srinivasan V; Iasevoli F; Tomasetti C; Valchera A; Perna G; Quera-Salva MA; Martinotti G; di Giannantonio M
Int J Mol Sci; 2013 Jun; 14(6):12458-83. PubMed ID: 23765220
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
12. [Development of a new antidepressant : agomelatine].
Mocaër E; Delalleau B; Boyer PA; de Bodinat C
Med Sci (Paris); 2005 Oct; 21(10):888-93. PubMed ID: 16197911
[TBL] [Abstract][Full Text] [Related]
13. Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Vengeliene V; Noori HR; Spanagel R
Neuropsychopharmacology; 2015 Dec; 40(13):2897-906. PubMed ID: 25994077
[TBL] [Abstract][Full Text] [Related]
14. Agomelatine attenuates alcohol craving and withdrawal symptoms by modulating the Notch1 signaling pathway in rats.
Fathi D; Abulsoud AI; Saad MA; Nassar NN; Maksimos MM; Rizk SM; Senousy MA
Life Sci; 2021 Nov; 284():119904. PubMed ID: 34453945
[TBL] [Abstract][Full Text] [Related]
15. Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.
Morley-Fletcher S; Mairesse J; Soumier A; Banasr M; Fagioli F; Gabriel C; Mocaer E; Daszuta A; McEwen B; Nicoletti F; Maccari S
Psychopharmacology (Berl); 2011 Oct; 217(3):301-13. PubMed ID: 21503609
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.
Racagni G; Riva MA; Molteni R; Musazzi L; Calabrese F; Popoli M; Tardito D
World J Biol Psychiatry; 2011 Dec; 12(8):574-87. PubMed ID: 21999473
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine, melatonin and depressive disorder.
Norman TR
Expert Opin Investig Drugs; 2013 Apr; 22(4):407-10. PubMed ID: 23484857
[TBL] [Abstract][Full Text] [Related]
19. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
20. Hormonal and behavioural abnormalities induced by stress in utero: an animal model for depression.
Maccari S; Darnaudery M; Van Reeth O
Stress; 2001 Sep; 4(3):169-81. PubMed ID: 22432138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
